Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...

We recently compiled a list of the Billionaire Israel Englander’s Top 10 Stock Picks Heading Into 2025. In this article, we ...

Zepbound, as expected, was more effective in promoting weight loss. Eli Lilly's Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...

As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA.

Shares of Eli Lilly & Co. LLY inched 0.50% higher to $781.98 Friday, on what proved to be an all-around positive trading ...

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some ...

Karyopharm Therapeutics Inc. (KPTI), a company focused on novel cancer therapies, said on Thursday that it has appointed Lori ...

(Image Credits: Pixabay) It has been a year since the launch of Zepbound (tirzepatide) for obesity, and Eli Lilly’s competition with Novo Nordisk continues. Zepbound’s superior efficacy and ...

Eli Lilly is intervening in a lawsuit filed by a trade group representing compounding pharmacies, aiming to block the FDA's determination that the shortage of its GLP-1 medications, Mounjaro and ...

Obesity is a major global health crisis, especially in the United States, but newer weight-loss drugs like Eli Lilly’s (LLY) Zepbound could offer a long-awaited solution — if they become more ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other healthcare stocks Jim Cramer has made bold predictions about. Healthcare has been ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...